دورية أكاديمية
أعرض في EDS

Structure-Based Analysis of Cefaclor Pharmacokinetic Diversity According to Human Peptide Transporter-1 Genetic Polymorphism.

التفاصيل البيبلوغرافية
العنوان: Structure-Based Analysis of Cefaclor Pharmacokinetic Diversity According to Human Peptide Transporter-1 Genetic Polymorphism.
المؤلفون: Jang JH; College of Pharmacy, Sunchon National University, 255 Jungang-ro, Suncheon-si 57922, Republic of Korea., Jeong SH; College of Pharmacy, Sunchon National University, 255 Jungang-ro, Suncheon-si 57922, Republic of Korea.; College of Pharmacy and Research Institute of Life and Pharmaceutical Sciences, Sunchon National University, Suncheon-si 57922, Republic of Korea.
المصدر: International journal of molecular sciences [Int J Mol Sci] 2024 Jun 22; Vol. 25 (13). Date of Electronic Publication: 2024 Jun 22.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, [2000-
مواضيع طبية MeSH: Peptide Transporter 1*/genetics , Peptide Transporter 1*/metabolism , Cefaclor*/pharmacokinetics, Humans ; Exons/genetics ; Genotype ; Polymorphism, Genetic ; Anti-Bacterial Agents/pharmacokinetics ; Polymorphism, Single Nucleotide ; Models, Molecular
مستخلص: Cefaclor is a substrate of human-peptide-transporter-1 (PEPT1), and the impact of inter-individual pharmacokinetic variation due to genetic polymorphisms of solute-carrier-family-15-member-1 ( SLC15A1 ) has been a topic of great debate. The main objective of this study was to analyze and interpret cefaclor pharmacokinetic variations according to genetic polymorphisms in SLC15A1 exons 5 and 16. The previous cefaclor bioequivalence results were integrated with additional SLC15A1 exons 5 and 16 genotyping results. An analysis of the structure-based functional impact of SLC15A1 exons 5 and 16 genetic polymorphisms was recently performed using a PEPT1 molecular modeling approach. In cefaclor pharmacokinetic analysis results according to SLC15A1 exons 5 and 16 genetic polymorphisms, no significant differences were identified between genotype groups. Furthermore, in the population pharmacokinetic modeling, genetic polymorphisms in SLC15A1 exons 5 and 16 were not established as effective covariates. PEPT1 molecular modeling results also confirmed that SLC15A1 exons 5 and 16 genetic polymorphisms did not have a significant effect on substrate interaction with cefaclor and did not have a major effect in terms of structural stability. This was determined by comprehensively considering the insignificant change in energy values related to cefaclor docking due to point mutations in SLC15A1 exons 5 and 16, the structural change in conformations confirmed to be less than 0.05 Å, and the relative stabilization of molecular dynamic simulation energy values. As a result, molecular structure-based analysis recently suggested that SLC15A1 exons 5 and 16 genetic polymorphisms of PEPT1 were limited to being the main focus in interpreting the pharmacokinetic diversity of cefaclor.
References: Eur J Pharm Biopharm. 2005 Jan;59(1):17-24. (PMID: 15567297)
Mol Aspects Med. 2013 Apr-Jun;34(2-3):323-36. (PMID: 23506874)
Antimicrob Agents Chemother. 2002 May;46(5):1273-80. (PMID: 11959556)
Drug Metab Dispos. 2006 Apr;34(4):547-55. (PMID: 16434549)
Biochem Pharmacol. 2007 Feb 1;73(3):440-9. (PMID: 17137557)
Pharmaceutics. 2019 Oct 14;11(10):. (PMID: 31614996)
Pflugers Arch. 2004 Feb;447(5):610-8. (PMID: 12905028)
J Chemother. 1999 Jun;11(3):163-78. (PMID: 10435677)
Pharm Res. 1999 Jan;16(1):55-61. (PMID: 9950279)
Antimicrob Agents Chemother. 1977 Nov;12(5):609-13. (PMID: 921258)
Sci Adv. 2021 Nov 05;7(45):eabk3259. (PMID: 34730990)
J Pharmacol Exp Ther. 2006 Feb;316(2):636-46. (PMID: 16258023)
Pharmaceutics. 2021 May 19;13(5):. (PMID: 34069627)
Biochim Biophys Acta. 1992 Dec 9;1112(2):167-73. (PMID: 1457450)
Eur J Med Chem. 2020 Dec 15;208:112829. (PMID: 33002736)
Pharmacotherapy. 1997 Jan-Feb;17(1):121-5. (PMID: 9017772)
Antimicrob Agents Chemother. 1978 Feb;13(2):210-3. (PMID: 646343)
معلومات مُعتمدة: RS-2023-00245453 National Research Foundation of Korea
فهرسة مساهمة: Keywords: PEPT1; SLC15A1 exons 5 and 16; cefaclor; inter-individual variability; pharmacokinetics
المشرفين على المادة: 0 (Peptide Transporter 1)
69K7K19H4L (Cefaclor)
0 (SLC15A1 protein, human)
0 (Anti-Bacterial Agents)
تواريخ الأحداث: Date Created: 20240713 Date Completed: 20240713 Latest Revision: 20240715
رمز التحديث: 20240715
مُعرف محوري في PubMed: PMC11241437
DOI: 10.3390/ijms25136880
PMID: 38999989
قاعدة البيانات: MEDLINE
الوصف
تدمد:1422-0067
DOI:10.3390/ijms25136880